Translate page

Nick Cross, MA PhD FRCPath 
Nick Cross

 

Nick Cross MA PhD FRCPath studies at the University of Cambridge, initially reading Natural
Sciences and subsequently undertaking a PhD in the Department of Genetics. He started his postdoctoral career at the Hammersmith Hospital, London in 1987, where he developed an interest in chronic myeloid leukaemia under the mentorship of Prof John Goldman. In 2001 he relocated to Salisbury to take up Directorship of the Wessex Regional Genetics Laboratory and Chair of Human Genetics at the University of Southampton. His research, which has resulted in more than 290 peer reviewed publications, focuses on the molecular pathogenesis of myeloid malignancies as well as the development, validation and standardisation of genetic tests.

 

Charles Schiffer Ausschnitt 

Charles A. Schiffer, MD, is Professor of Medicine and Oncology at Wayne State University School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan. He is the director of the Leukemia/Lymphoma Multidisciplinary Program.

 

Dr. Schiffer earned his BA cum laude at Brandeis University and his M.D. at New York University School of Medicine. He completed his internship, residency, and chief residency in Internal Medicine at Bellevue Hospital under the auspices of New York University School of Medicine and had subsequent training and positions at the Baltimore Cancer Research Institute, National Cancer Institute and the University of Maryland School of Medicine, where he served as Chief of the Division of Hematology. He has also served as Chief of the Division of Hematology/Oncology and Director of Clinical Research at the Karmanos Cancer Institute.

 

Dr. Schiffer has authored and co-authored more than 300 articles and 80 book chapters on topics concerning the treatment of leukemia in adults, platelet transfusion, and granulocyte transfusion therapy, among others. He has served on the Editorial Boards for Blood, the Journal of Clinical Oncology, International Journal of Hematology, Transfusion Medicine Reviews and Transfusion, and reviews articles for multiple journals. Committee memberships have included Chairman of the Leukemia Committee of the Cancer and Leukemia Group B, Chairman of the Food and Drug Administration Oncologic Drug Advisory Committee, and grant reviews for the NCI and Leukemia/Lymphoma Society of America. Dr. Schiffer has been named among American Health Magazine’s and Castle Connelly’s “Best Doctors in America,” “Best Cancer Specialists in the US.” In 2006, he received the Dr. John J. Kenney Award from the Leukemia/Lymphoma Society of America and the Celgene Award for Career Achievement in Hematology. He has received multiple teaching awards from Wayne State University and was recently inducted into the Academy of Scholars, the highest recognition accorded to academic faculty at the University.

hochhaus_andreas

Universitätsklinikum Jena

Jena, Germany

 

Andreas Hochhaus is a Professor of Internal Medicine, Hematology and Oncology and interim Head of the Department of Hematology and Medical Oncology at the University Medical Center Jena in Germany. He was awarded the Endowed Professorship for Leukemia Research from the German José Carreras Leukemia Foundation in 2007.

He has been interested in treatment optimization of chronic myelogenous leukemia (CML) and has been involved in the management of the randomized CML Studies I-IV of the German CML Study Group for more than 19 years. His special interests are the molecular monitoring of minimal residual disease and mechanisms of resistance in CML, and targeted therapy in a variety of neoplastic disorders.

Dr. Hochhaus is investigator for the nilotinib, dasatinib and bosutinib phase II and phase III studies, has been participating in imatinib phase II and III studies and is conducting trials of imatinib combined with pegylated interferon alpha, lonafarnib and everolimus.

He is a member of the European Hematology Association, the American Society of Hematology, the American Society of Clinical Oncology, the International Society of Hematology, the International Association for Comparative Research on Leukemia and Related Diseases, and the German Society for Hematology and Oncology. He has published over 240 peer-reviewed papers and is regularly invited to speak at national and international symposia.

 

jan_geissler_200wJan Geissler

Chair, LeukaNET / Leukämie-Online, Germany

Co-Founder, CML Advocates Network

 

In July 2001, Jan received his diagnosis of a rare cancer, Chronic Myeloid Leukemia (CML), at a routine check-up. He then joined a phase I/II clinical trial. As hardly any information on upcoming treatments was available in the German language, he started to simplify and translate medical publications into German language. In 2002, he started to publish them by founding the online patient community Leukämie-Online (http://www.leukaemie-online.de), which is one of the most frequented patient websites on leukemia in the German speaking Internet today. Leukämie-Online became a charitable organisation in Germany in 2006, with Jan being the Chair.

In 2007, Jan has co-founded the CML Advocates Network (http://www.cmladvocates.net) together with other CML patient groups from Israel, the UK and Czech Republic. The goal of the web-based platform is to get organisations connected that are supporting patients with Chronic Myeloid Leukemia. Today, members include 57 CML groups from all continents, sharing best practice in cancer patient advocacy and campaigning for better treatment and care of CML patients world wide.

Jan is also a co-founder of the European Cancer Patient Coalition (ECPC), a board member of the European Forum for Good Clinical Practice (EFGCP), and acts on a number of advisory boards.

In the International CML Foundation (iCMLf), Jan acts as Communications Coordinator and runs the foundation's Pediatric CML program.

Contact

Jan Geissler <jan@cml-foundation.org>

 

susan-branfordSusan Branford, MD

Centre for Cancer Biology,
SA Pathology and Adelaide University
Adelaide, Australia

 

 

Dr. Susan Branford holds the position of an Associate Professor at the School of Medicine and the School of Molecular and Biomedical Science of Adelaide University in Australia. She has special expertise in molecular monitoring of the BCR-ABL gene for patients with chronic myeloid leukaemia. As such she is a major contributor to international collaborative initiatives to establish guidelines and recommendations for producing reliable molecular data. Dr. Branford's main research is focused on the formation of the BCR-ABL gene, the mechanisms of kinase inhibitor drug resistance and the factors that predict for response to therapy and the development of drug resistance.

 

suttorpMeinolf Suttorp, MD

Dresden University Childrens' Hospital

Dresden, Germany

 

Meinolf Suttorp is Professor of Pediatrics and Head of the Division of Pediatric Hematolgy, Oncology, and Stem cell transplantation at Dresden University Childrens' Hospital in Dresden, Germany. Prof. Meinolf Suttorp obtained his academic degrees in Organic Chemistry from the University of Münster, Germany and in Human Medicine from the University of Kiel, Germany. He completed his clinical training during his residency in Pediatrics at the Pediatric Dept. of the Children's Hospital, University of Kiel. His research interests include the development of chimerism following allogeneic stem cell transplantation , strategies for optimisation of chronic myeloid leukemia (CML) treatment in children, the molecular characterization of the chromosomal translocation t(9;22) as well as techniques for detection of minimal residual disease in childhood CML. Prof. Meinolf Suttorp is the chairman of ongoing national and international trials on treatment of CML in pediatrics . He is  active  member of multiple societies in the field of Hematology/Oncology (ASH, EBMT, GPOH, I-BFM).  He has authored or co-authored book chapters and numerous international peer-reviewed articles including Blood, Leukemia, Hematology, Bone Marrow Transplantation, Pediatric Blood & Cancer, Klinische Pädiatrie.